Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL254 Target Snapshot

3',5'-cyclic-AMP phosphodiesterase 4A · SINGLE PROTEIN · Homo sapiens

1,984Compounds
143Assays
6Approved Drugs
1,267.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P27815. Use UniProt P27815 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P27815 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3',5'-cyclic-AMP phosphodiesterase 4A as ChEMBL target CHEMBL254, mapped to UniProt P27815. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3',5'-cyclic-AMP phosphodiesterase 4A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL254
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P27815
3',5'-cyclic-AMP phosphodiesterase 4A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 3',5'-cyclic-AMP phosphodiesterase 4A is the right protein anchor across sources, using UniProt P27815 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label3',5'-cyclic-AMP phosphodiesterase 4A
UniProt AccessionP27815
Component TypeProtein
Sequence Length886 aa

3',5'-cyclic-AMP phosphodiesterase 4A

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as 3',5'-cyclic-AMP phosphodiesterase 4A, mapped to UniProt P27815. Sequence length is 886 aa.

Mapped IDP27815
Review name3',5'-cyclic-AMP phosphodiesterase 4A
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

6
Approved
2
Phase III
13
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,137.0
KI110.0
EC5020.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5417689 10.5 IC50 0.03162 Preclinical
CHEMBL499477 10.22 IC50 0.06 Preclinical
CHEMBL127944 10.15 IC50 0.07 Preclinical
CHEMBL3676245 10.0 IC50 0.1 Preclinical
CHEMBL377709 10.0 IC50 0.1 Preclinical
CHEMBL380321 10.0 IC50 0.1 Preclinical
CHEMBL382168 10.0 IC50 0.1 Preclinical
CHEMBL5892052 10.0 IC50 0.1 Preclinical
CHEMBL2402362 9.82 IC50 0.15 Preclinical
CHEMBL381681 9.8 IC50 0.16 Preclinical
Distribution

pChEMBL Value Distribution

74
5.0
59
5.5
121
6.0
141
6.5
144
7.0
171
7.5
144
8.0
94
8.5
72
9.0
19
9.5
pChEMBL
Approved Drugs

Approved Drugs

CRISABOROLE
CHEMBL484785
Approved 2016
ROFLUMILAST
CHEMBL193240
Approved 2010
IBUDILAST
CHEMBL19449
Approved 1989
Assay Landscape

Assay Landscape

143
Total Assays
980
Tested Compounds
3
Assay Types
Binding — 134 assays, 980 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 86 577 7.3
cell-based format 37 205 7.6
assay format 11 198 7.1
Functional — 5 assays, 24 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 3 7.5
tissue-based format 1 21 5.4
ADME — 4 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 6 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine